Photo of Joshi J. Alumkal, MD

Joshi J. Alumkal MD

Dr. Alumkal's research interest is cancer epigenetics, the study of heritable and potentially reversible changes in gene expression in cancer. His laboratory studies key chromatin modifying enzymes in cancer with an eye towards: 1) elucidating their function and role in transformation and disease progression and 2) targeting them with pharmacological agents in order to improve our ability to prevent and treat men with prostate cancer. Finally, his laboratory also focuses on the identification of biomarkers associated with prostate cancer development or aggressiveness.


  • M.D., Baylor College of Medicine 1998
  • Residency:

    • University of Texas, Southwestern Medical Center, 2002
  • Fellowship:

    • Fellowship in medical oncology, Johns Hopkins University School of Medicine, 2006
  • Certifications:

    • American Board of Internal Medicine (internal medicine), 2001

Memberships and associations

  • American College of Physicians


  • "DNA repair gene alterations and PARP inhibitor response in patients with metastatic castration-resistant prostate cancer." JNCCN Journal of the National Comprehensive Cancer Network In: , Vol. 16, No. 8, 01.08.2018, p. 933-937.
  • "Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL." Oncogene In: , 30.05.2018, p. 1-12.
  • "LSD1 activates a lethal prostate cancer gene network independently of its demethylase function." Proceedings of the National Academy of Sciences of the United States of America In: , Vol. 115, No. 18, 01.05.2018, p. E4179-E4188.
  • "Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer." Journal of the National Cancer Institute In: , Vol. 109, No. 12, 01.12.2017.
  • "Analysis of circulating cell-free DnA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors." Cancer Discovery In: , Vol. 7, No. 9, 01.09.2017, p. 999-1005.
  • "Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer." European Journal of Cancer In: , Vol. 81, 01.08.2017, p. 228-236.
  • "Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone." Clinical Cancer Research In: , Vol. 23, No. 14, 15.07.2017, p. 3544-3551.
  • "Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer : post hoc analysis of PREVAIL." Prostate Cancer and Prostatic Diseases In: , 24.01.2017.
  • "Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?" JAMA oncology In: , Vol. 3, No. 1, 01.01.2017, p. 11-12.
  • "Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer." Oncotarget In: , Vol. 8, No. 67, 01.01.2017, p. 111084-111095.
  • "Falls and Frailty in Prostate Cancer Survivors : Current, Past, and Never Users of Androgen Deprivation Therapy." Journal of the American Geriatrics Society In: , 2017.
  • "High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer." Clinical Genitourinary Cancer In: , 2017.
  • "Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide." Annals of Oncology In: , Vol. 28, No. 9, 2017, p. 2264-2271.
  • "CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer : Factors Predictive of Maximum Tumor Yield." Journal of Vascular and Interventional Radiology In: , 19.12.2016.
  • "Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial." Clinical Genitourinary Cancer In: , 14.12.2016.
  • "Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer : Update on the Stand Up 2 Cancer/Prostate Cancer Foundation–Supported West Coast Prostate Cancer Dream Team." European Urology Focus In: , Vol. 2, No. 5, 01.12.2016, p. 469-471.
  • "Raising the bar for therapeutic trials in advanced prostate cancer." Journal of Clinical Oncology In: , Vol. 34, No. 25, 01.09.2016, p. 2958-2960.
  • "Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer." Oncotarget In: , Vol. 7, No. 33, 01.08.2016, p. 52810-52817.
  • "Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor." Oncotarget In: , Vol. 7, No. 26, 2016, p. 40690.
  • "Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort." European Urology In: , 2016.
  • "Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2 : ERG fusion-positive versus fusion-negative tumors." Clinical Epigenetics In: , Vol. 7, No. 1, 128, 12.12.2015.
  • "Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic castration-resistant prostate cancer : A Department of Defense Prostate Cancer Clinical Trials Consortium randomized phase II trial of intermittent docetaxel with prednisone with or without maintenance GM-CSF." Clinical Genitourinary Cancer In: , Vol. 13, No. 3, 349, 01.06.2015, p. e191-e198.
  • "AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - Results of two parallel first-in-human phase I studies." Investigational New Drugs In: , Vol. 33, No. 3, 30.04.2015, p. 679-690.
  • "A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer." Investigational New Drugs  In: , Vol. 33, No. 2, 01.04.2015, p. 480-489.
  • "Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival : Results from American College of Radiology Imaging Network 6687." Journal of Nuclear Medicine In: , Vol. 56, No. 3, 01.03.2015, p. 354-360.
  • "CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non-small cell lung cancer." Discovery medicine In: , Vol. 19, No. 104, 2015, p. 151-158.
  • "Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen." Clinical Cancer Research In: , Vol. 20, No. 16, 15.08.2014, p. 4218-4227.
  • "Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer." Investigational New Drugs In: , Vol. 32, No. 5, 26.04.2014, p. 904-912.
  • "Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer." PLoS One  In: , Vol. 9, No. 3, e91666, 13.03.2014.
  • "Orteronel for the treatment of prostate cancer." Future Oncology In: , Vol. 10, No. 5, 2014, p. 803-811.

Additional information

Edit profile